Please login (Members) to view content or
(Nonmembers) this article.

No votes yet

CNE Article

CAR T-Cell Therapy: Pediatric Patients With Relapsed and Refractory Acute Lymphoblastic Leukemia

Colleen Callahan
Diane Baniewicz
Beth Ely
CJON 2017, 21(2), 22-28 DOI: 10.1188/17.CJON.S2.22-28

Background: Immunotherapy provides a promising treatment option for children and adolescents with refractory or relapsed acute lymphoblastic leukemia (ALL). 

Objectives: This article presents a hospital’s experience with providing chimeric antigen receptor (CAR) T-cell therapy, followed by a detailed discussion of the trajectory of treatment provided for pediatric patients and their families.

Methods: Clinical experience in delivering care to pediatric patients undergoing CAR T-cell therapy is described. Care coordination, patient and family assessment and education, and post–CAR T-cell infusion monitoring are presented. 

Findings: Of 59 patients having been treated with CAR T-cell therapy at the authors’ institution, 93% had a complete response at day 28. The 12-month relapse-free survival rate is 55%. A multidisciplinary team of skilled clinicians is recommended to support patient and family needs throughout screening, treatment, and follow-up while coordinating care with the referring oncologist.

Earn contact hours: ONS members can receive free CNE for reading this article and completing an evaluation online. To do so, click HERE or visit to access a current list of all available activities. This article's CNE is available for two years from the date of publication.

Members Only

Access to this article is restricted. Please login to view the full article.

Not a current ONS Member or journal subscriber?
Join/Renew Membership or